Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors

Trial Profile

Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ecubectedin (Primary) ; Irinotecan (Primary)
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Biliary cancer; Bladder cancer; Breast cancer; Carcinoma; Cervical cancer; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Gastric cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 08 Jun 2021 Results (n=37) assessing safety, efficacy and pharmacokinetics of PM14 in patients with advanced solid tumors, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
    • 22 Sep 2017 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top